Portal de Periódicos da CAPES

Interleukin-21 Augments the Efficacy of T-Cell Therapy by Eliciting Concurrent Cellular and Humoral Responses

2008; American Association for Cancer Research; Volume: 68; Issue: 11 Linguagem: Inglês

10.1158/0008-5472.can-07-5530

1538-7445

Takekazu Iuchi, Seagal Teitz‐Tennenbaum, Jianhua Huang, Bruce G. Redman, Steven D. Hughes, Mu Li, Guihua Jiang, Alfred E. Chang, Qiao Li,

Immunotherapy and Immune Responses

Abstract Interleukin (IL)-21 modulates T-cell–associated, B-cell–associated, and natural killer cell–associated immunity. However, the potential of IL-21 to simultaneously stimulate cellular and humoral antitumor responses and the mechanisms involved have not yet been adequately explored. In this report, we examined the immune-modulating effect of IL-21 when used in vitro and its adjuvant effects when administrated concomitantly with T-cell transfer for cancer therapy. Use of IL-21 in concert with IL-2 in culture up-regulated both type 1 and type 2 cytokine production of activated tumor-draining lymph node cells and enhanced their therapeutic efficacy. Administration of IL-21 and IL-2 as an adjuvant to T-cell transfer resulted in simultaneously elicited cellular and humoral responses. This concurrent response has led to effective regression of established pulmonary metastatic tumors and s.c. tumors. T-cell transfer plus IL-21/IL-2 administration conferred systemic immunity to the treated hosts. This was evident by the induction of protective immunity against tumor rechallenge, expansion of memory T cells, and significantly elevated serum levels of IFNγ and IL-10. Furthermore, we observed significantly enhanced tumor-associated antibody response after T-cell + IL-2 + IL-21 therapy. Cytotoxic antibody subclass IgG2b increased strikingly in the sera of treated animals; they bound specifically to MCA205 tumor cells, and such immune sera mediated tumor cell lysis in the presence of complement. Use of B-cell–deficient mice provided direct evidence that humoral responses contribute to T-cell + IL-2 + IL-21–elicited antitumor immunity. Collectively, these findings provide a rationale to evaluate the use of IL-21 in T-cell therapy of human cancers. [Cancer Res 2008;68(11):4431–41]